[Abstract]2025 Dec;333(Pt 1):148831
It is important to inform your healthcare provider of any allergies or sensitivities
In Phase II trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Harma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc
After the FDA resolved the shortages, compounded GLP-1s are no longer available simply because they are cheaper
However, further studies are needed to elucidate the safety of other drugs in the class for patients that experience a hypersensitivity reaction to one GLP-1 receptor agonist
For Egrifta specifically, the approved prescribing information states the reconstituted product should be used promptly